Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study of Oral Infigratinib in Adult Patients With Advanced or Metastatic Solid Tumors With FGFR1-3 Gene Fusions or Other FGFR Genetic Alterations

NCT04233567 is registered in ClinicalTrials.gov with Sameek Roychowdhury as lead sponsor.

NCT NCT04233567
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04233567 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study of Oral Infigratinib in Adult Patients With Advanced or Metastatic Solid Tumors With FGFR1-3 Gene Fusions or Other FGFR Genetic Alterations
Lead sponsor
Sameek Roychowdhury
Phase
Phase 2
Overall status
Completed
Start date
January 16, 2020
Completion date
December 12, 2024
Enrollment
17 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

advanced malignant solid neoplasm, cholangiocarcinoma, metastatic malignant solid neoplasm, refractory malignant solid neoplasm